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Abstract
Background: We have previously outlined functional interactions, including feedback cycles, between several of
the gene products implicated in the pathogenesis of Alzheimer’s disease. A number of Alzheimer-related stressors
induce neuronal expression of apolipoprotein E (ApoE), b-amyloid precursor protein (bAPP), and fragments of the
latter such as amyloid b-peptide (Ab) and secreted APP (sAPP). These stressors include interleukin-1 (IL-1)-mediated
neuroinflammation and glutamate-mediated excitotoxicity. Such circumstances are especially powerful when they
transpire in the context of an APOE ε4 allele.
Methods: Semi-quantitative immunofluorescence imaging was used to analyze rat brains implanted with IL-1b
slow-release pellets, sham pellets, or no pellets. Primary neuronal or NT2 cell cultures were treated with IL-1b,
glutamate, Ab, or sAPP; relative levels of ApoE mRNA and protein were measured by RT-PCR, qRT-PCR, and western
immunoblot analysis. Cultures were also treated with inhibitors of multi-lineage kinases–in particular MAPK-p38
(SB203580), ERK (U0126), or JNK (SP600125)–prior to exposure of cultures to IL-1b, Ab, sAPP, or glutamate.
Results: Immunofluorescence of tissue sections from pellet-implanted rats showed that IL-1b induces expression of
bAPP, IL-1a, and ApoE; the latter was confirmed by western blot analysis. These protein changes were mirrored by
increases in their mRNAs, as well as in those encoding IL-1b, IL-1b-converting enzyme (ICE), and tumor necrosis
factor (TNF). IL-1b also increased ApoE expression in neuronal cultures. It stimulated release of sAPP and glutamate
in these cultures too, and both of these agents–as well as Ab–stimulated ApoE expression themselves, suggesting
that they may contribute to the effect of IL-1b on ApoE levels. Inhibitors of MAPK-p38, ERK, and JNK inhibited
ApoE induction by all these agents except glutamate, which was sensitive only to inhibitors of ERK and JNK.
Conclusion: Conditions of glial activation and hyperexcitation can elevate proinflammatory cytokines, ApoE,
glutamate, bAPP, and its secreted fragments. Because each of these factors promotes glial activation and neuronal
hyperexcitation, these relationships have the potential to sustain self-propagating neurodegenerative cycles that
could culminate in a progressive neurodegenerative disorder such as Alzheimer’s disease.
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Introduction
The pluripotent glial cytokine interleukin-1 (IL-1) and
the CNS-abundant, lipid-cholesterol-carrying protein
apolipoprotein E (ApoE) are key participants in the
pathogenesis of Alzheimer’s disease (AD). ApoE contri-
butes both to learning and to recovery from neural
injury [1], perhaps by enhancing synaptogenesis by
influencing Reelin signaling [2,3]. In humans, single-
nucleotide polymorphisms in the coding region of the
ApoE gene (APOE) yield three alleles (ε2, ε3, ε4) that
translate into three distinct protein sequences, ApoE2,
ApoE3, and ApoE4. Inheritance of the particular isoform
of ApoE encoded by the ε4 variant of the APOE gene
confers significant risk for precocious development of
AD [4,5]: those with two copies of the ε4 allele of APOE
have a 50-90% chance of developing AD by the age of
85, and even one copy confers a three-fold increase in
risk over individuals with no ε4 alleles [6]. Though
ApoE is primarily expressed in astrocytes in the healthy
brain, stressors can induce its expression in neurons
[7,8].
Although not as strongly associated with AD risk as
possession of ApoE4 sequences, specific polymorphisms
in the genes encoding IL-1a and IL-1b are also asso-
ciated with increased AD risk. Specifically, variations in
the promoter region of IL1A and in the coding region of
IL1B influence AD risk when homozygous in one gene
or heterozygous in both [9-13]. Glial activation marked
by excess production of both IL-1a and b is a constant
feature in several conditions associated with increased
risk for precocious development of AD: i) traumatic
brain injury (TBI) [14], ii) systemic viral disease, e.g.,
AIDS [15]; iii) the neuronal hyperexcitability of epilepsy
[16-19]; iv) chromosome 21 anomalies such as Down’s
syndrome [20]; and v) advancing age [21-23]. Each of
these stressors is associated with precocious develop-
ment of AD [18,24,25], especially in those who have
inherited one or more ε4 alleles of APOE [1,26-29].
Excess production and secretion of IL-1b elevates neu-
ronal expression of the precursors of each of the
changes characteristic of AD. These neurodegeneration-
related precursors include b-amyloid precursor protein
(bAPP), which may lead in vivo to deposition of Ab [30]
and further induction of IL-1b [31]; ApoE, which is pre-
sent in plaques [32] and necessary for the accumulation
of Ab deposits [33]; and hyperphosphorylated tau [5],
the principal component of neurofibrillary tangles. IL-1
also induces a-synuclein [34], the Lewy body precursor.
Despite the potential for contributing to the produc-
tion of Ab, elevations of bAPP may participate in com-
pensatory responses. bAPP is elevated in response to
stressors beyond IL-1b, including excitotoxins and age
itself, yet AD pathology is correlated with a deficiency
in bAPP expression [35]. ApoE appears to mediate the
compensatory induction of bAPP; blocking ApoE synth-
esis or its receptors inhibits the effect of glutamate on
bAPP [35]. bAPP knockout mice show learning and
memory deficits [36] and die prematurely [37]; secreted
bAPP (sAPP) is generally neuroprotective [38]. Taken
together, these findings suggest that possession of an ε4
allele or ApoE insufficiency compromises neurological
parameters and exacerbates injury-induced deficits at
least in part by limiting inductions of bAPP. ApoE,
especially ApoE3, may also serve to keep inflammatory
reactions in check [39-41]. A possible mechanism is
suggested by the ability of ApoE to suppress the proin-
flammatory activity of sAPP [31].
In AD, activated microglia overexpressing IL-1 are
present in diffuse Ab deposits prior to the appearance
of ApoE [32]. With normal aging, the brain shows
increased microglial activation and expression of IL-1
[21], as well as neuronal expression of both ApoE and
bAPP [35]. The ability of IL-1b to induce bAPP expres-
sion [30,42] raises the question of whether this is a
direct mechanism or an indirect phenomenon resulting
from ApoE induction, similar to the effect of glutamate
[35]. In view of the relations between the AD-related
stressors and the importance of ApoE in risk for devel-
opment of AD, together with the neuropathological
changes observed in AD patients, we tested the hypoth-
esis that ApoE would be elevated in CNS neurons sec-
ondary to several AD-related stressors associated with
excessive expression of IL-1. Specifically, rat primary
cortical neurons and a neuropotent human cell line
(NTera2) were assessed for ApoE expression after treat-
ment with IL-1b, sAPP, glutamate, or Ab. To delineate
the roles of multi-lineage kinase (MLK) pathways in the
induction of neuronal ApoE expression, we utilized inhi-
bitors of p38-MAPK, ERK, and JNK pathways. To deter-
mine if such changes in ApoE expression might be
observed in vivo, and the potential relationship of such
changes to other proteins that are induced by IL-1, we
measured the expression of ApoE, bAPP, and other neu-




Pellets (1.5 mm in diameter, designed for controlled
slow release of compounds over a 21-day period; Inno-
vative Research of America, Sarasota, FL) impregnated
with IL-1b (100 ng recombinant mouse IL-1b; Sigma
Chemical Company, St. Louis, MO) and ‘control’ pellets
(with bovine serum albumin) were implanted 2.8 mm
caudal to bregma, 4.5 mm right of the midline, and 2.5
mm below the pial surface. Twenty-one male Sprague-
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Dawley rats, weighing 264 ± 6 g, were randomly
assigned to three groups. Eight rats received implants of
21-day timed-release IL-1b-containing pellets, seven rats
received sham (vehicle) pellets, and six rats served as
unoperated controls. Twenty-one days after implanta-
tion, cortices from left hemispheres were collected for
protein and mRNA isolation. For histological study,
brain tissues were fixed in 10% formalin, embedded in
paraffin, sectioned at 7 μm, and prepared for immuno-
histochemical analysis. All animal studies were con-
ducted in accordance with a protocol reviewed and
approved by the Institutional Animal Care and Use
Committee of the Central Arkansas Veterans Healthcare
System.
Reagents
Rat recombinant mature IL-1b (IL-1b holoprotein clea-
vage product) was purchased from Sigma (St. Louis
MO), secreted APP (sAPP) was purified from a recombi-
nant expression system as described previously [42], and
L-glutamate was from Sigma (St. Louis MO). Ab1-42,
from US Peptide Inc. (Rancho Cucamonga CA), was dis-
solved in DMSO and then incubated at 4°C overnight
prior to use. Rabbit anti-mouse IL-1b antibody was
from Chemicon (Temecula CA); goat anti-human apoli-
poprotein E was from Calbiochem (Sunnyvale CA). Inhi-
bitors of the p38-MAPK (SB203580), ERK (U0126), and
JNK (SP600125) pathways were from Calbiochem. Med-
ium, serum, and B27 supplement for cell cultures were
from Invitrogen/Life Technologies (Grand Island NY).
The antibodies used were rabbit anti-human IL-1a
(Peprotech 4:1000), goat anti-human APP (ADI 1:50),
goat anti-Human APO E (Invitrogen 1:50), diluted in
antibody diluent (Dako, Carpiteria CA).
Immunofluorescence
For immunofluorescent analysis of brain tissues, paraffin
blocks were sectioned at 7 μm and placed on pre-
cleaned microscope slides (Fischer). Then, sections were
deparaffinized in xylene, rehydrated in graduated etha-
nol solutions to deionized water. For IL-1a immunor-
eactions, sections were placed in boiling sodium citrate
buffer (0.01 M, pH 6.0) for 20 minutes. Sections for
bAPP and ApoE were placed in trypsin solution for 10
minutes at 37°C, all sections were blocked using protein
block (Dako). For each antibody, sections were incu-
bated overnight at room temperature. The secondary
antibodies, Alexa Fluor donkey anti-goat and donkey
anti-rabbit were diluted in antibody diluent (Dako) and
sections were incubated for 60 minutes. The sections
were then washed in three changes 5 minutes each of
distilled H2O and then coverslipped with prolong Gold
with DAPI (Invitrogen).
Image Analysis
Similar to our previous study [35], a quantitative
approach was used to examine mean intensities of
immunoreactions. Three representative images per slide
(40× magnification) from IL-1-pellet, sham, and unoper-
ated rat brains were obtained at identical exposure set-
tings, using a Nikon Eclipse E600 microscope equipped
with a Coolsnap monochrome camera. Each of the three
images in each tissue section spanned a total area of
37241.5 μm2. These images were from hippocampal
CA1 and two cortical regions, one at the midline and
another at the superior aspects of the temporal cortex
and were acquired and analyzed using NIS-Elements
BR3 software (Nikon.com). All cells of a type were cap-
tured, and images were thresholded. Data obtained from
cells in each of the three regions were averaged, thus
providing a single value for each image, and this value
was used for statistical analysis. Data were analyzed by
ANOVA to assess difference among groups. A statistical
value of p ≤ 0.05 was defined as being significant.
Cell Cultures
Primary neuronal cultures were derived from cerebral
cortex of fetal Spraque-Dawley rats (embryonic day 18),
as previously described [43]. Experiments using primary
neuronal cell cultures were performed after 10-14 days in
culture. Highly purified cultures of rat microglia and
astrocytes were generated from the cortical tissue of neo-
natal (0-3 days) Sprague-Dawley rats, as described pre-
viously [43,44]. The NTera2 human cell line (Stratagene,
La Jolla, CA) was maintained in Dulbecco’s modified
Eagle medium (DMEM; Invitrogen/Life Technologies,
Grand Island, NY) supplemented to 10% with fetal bovine
serum (FBS). For specific experiments, SB203580 (5 μM),
U0126 (5 μM), or SP600125 (5 μM) was applied to cul-
tures one hour before application of a stimulus. Gluta-
mate released in the culture medium was assayed with a
kit that utilizes a glutamate dehydrogenase-coupled color
reaction (Roche Diagnostics, Indianapolis IN).
Reverse Transcription (RT) Reaction and Polymerase Chain
Reaction (PCR) Amplification
Total RNA was extracted from cultured cells using
TriReagent™ RNA (Molecular Research Center Inc.,
Cincinnati OH) according to the manufacturer’s instruc-
tions. Gel-based RT-PCR was performed as described
previously [45]. Briefly, RT reactions were performed
simultaneously using reagents from a single master mix,
and PCR was performed using reagents from Clontech
(Palo Alto CA). Aliquots of the product were resolved
on agarose gels, ethidium bromide staining was captured
by digital camera, and pixel intensities were quantified
with Scion Image 4.0.3.2. Conditions were established to
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ensure that maximal cycle number fell within the linear
phase of amplification. Real-time (quantitative) RT-PCR
was performed as described previously [35]. RT utilized
random hexamers for priming, and PCR was performed
with the Power SYBR-Green PCR Master Mix in an ABI
7900 HT Fast Real-time PCR System (Applied Biosys-
tems, Foster City, CA). Signals were interpolated within
standard curve reactions performed for each primer set,
and the result for ApoE was expressed as a fraction of
the 18S signal for each sample. All primer sequences,
annealing temperatures, and number of cycles are pro-
vided in Table 1.
Western Immunoblot Assay
Cellular fractions were prepared by application of a lysis
buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1%
Nonidet P40, 0.5% sodium deoxycholate and 0.1% SDS)
to the cultures after a wash with cold PBS. Tissue sam-
ples were prepared by homogenization in RIPA buffer
(Cell Bioscience) as described previously [35,42]. Lysates
were quantified using a Micro BCA assay reagent kit
(Pierce, Rockford IL) as described previously [43]. Ali-
quots (100 μg each) were resolved by SDS-PAGE, sub-
jected to electrophoresis at 70 V for 20 minutes and 90
V for 1.5 h, and transferred to nitrocellulose mem-
branes. After transfer, each blot was stained with Pon-
ceau S to ensure even loading of protein across lanes.
Blots were then blocked in I-Block Buffer (Applied Bio-
system Inc., Bedford, MA) for 45 minutes, then incu-
bated overnight at 4°C with goat anti-human ApoE
(1:2000) primary antibody, incubated for 1 h at room
temperature with alkaline phosphatase-conjugated sec-
ondary antibody, and developed using the Western-
Light™ Chemiluminescent Detection System (Applied
Biosystem Inc) and exposure to x-ray film. Digital
images were captured and analyzed using NIH Image
software, version 1.60.
Statistical Analysis
Comparisons between two conditions were made via
unpaired t-test, and experiments with a greater number
of variables were subjected to ANOVA with Fisher’s
post hoc test. Differences were considered significant at
p-values ≤0.05.
Results
Chronic IL-1b increases the expression of ApoE, bAPP,
and neuroinflammatory factors in rat brain
Rats were implanted with either slow-release (21-day)
IL-1b-impregnated pellets or vehicle-impregnated sham
pellets. Cerebral cortices from these rats, as well as
unoperated control rats, were processed for protein or
mRNA tissue level analyses or were fixed and processed
for immunofluorescent image analyses. Rat brains
implanted with IL-1b-containing pellets had markedly
elevated steady-state levels of ApoE mRNA (Figure 1A,
B) and of ApoE protein (Figure 1C,D) compared to
those in rats implanted with sham pellets or to unoper-
ated controls (p < 0.01).
Neuroinflammatory conditions and models thereof
often exhibit chain reactions of multiple effectors work-
ing sequentially, in parallel, or in feedback loops
fomenting a persistent and progressive situation. In this
vein, the ability of IL-1b to elevate the levels of IL-a
prompted an examination of gene-expression indices of
neuroinflammation in this chronic IL-1b delivery para-
digm. The increase in IL-1a immunofluorescence noted
above was found to be reflected at the mRNA level (Fig-
ure 2). Chronic IL-1b also elevated mRNA levels of
endogenous IL-1b, as well as its cleavage enzyme ICE
(Figure 2). Along with these changes in IL-1-related
molecules, the mRNA for the proinflammatory cytokine






ApoE F: TGT TGG TCC CAT TGC TGA CAG
GAT
60 25
R: TGG TGT TTA CCT CGT TGC GGT
ACT
bAPP F: CCC TGA CGC AGT CGA CAA GT 61 25
R: TGT CAT AAC CTG GGA CCG GAT
GAPDH F: CAA CGG ATT TGG CCG TAT TG 61 25
R: TGG GGG TAG GAA CAC GGA A
ICE F: ACA AAG AAG GTG GCG CAT TTC 61 28
R: CCT TGT TTC TCT CCA CGG C
IL-1a F: GAG TCA ACT CAT TGG CGC TTG 60 27
R: GGG CTG ATT GAA ACT TAG CCG
IL-1b F: TGA CTC GTG GGA TGA TGA CG 61 27
R: CTG GAG ACT GCC CAT TCT CG
TNF F: GCA CAG AAA GCA TGA TCC GAG 64 28
R: CCT GGT ATG AAG TGG CAA ATC G
Gel-based PCR, human
ApoE F: TTC TGT GGG CTG CGT TGC TG 60 25
R: TAC ACT GCC AGG CGC TTC TG
GAPDH F: AGG TCG GAG TCA ACG GAT TTG 61 25
R: TGG CAG GTT TTT CTA GAC GGC
Real-time PCR (rat)
ApoE F: CTG GTT CGA GCC GCT AGT G 60 N.A.
R: CCT GTA TCT TCT CCA TTA GGT TTG
C
18S F: TTC GAA CGT CTG CCC TAT CAA 60 N.A.
R: ATG GTA GGC ACG GCG ACT A
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TNF was elevated. These proinflammatory changes were
accompanied by induction of bAPP mRNA (Figure 2),
consistent with the immunofluorescence results and
prior studies of IL-1/bAPP interactions.
The induction of ApoE in the cortex by IL-1b pellets
was also detectable by immunofluorescence (Figure 3A),
which demonstrated neuronal localization. IL-1b pellets
also elevated expression of IL-1a in the CA1 of hippo-
campus (Figure 3B). This IL-1a induction was localized
principally to cells with astrocytic morphology. Pyrami-
dal neurons of the CA1 overexpressed bAPP in response
to the chronic delivery of IL-1b (Figure 3C).
Tissue culture studies reveal potential for indirect impacts
of IL-1b on ApoE
To examine the impact of IL-1b on ApoE expression in
greater temporal and mechanistic detail, we utilized two
types of neuronal cell culture: primary cultures of rat
cortical neurons and the human NTera2 (NT2) cell line.
We previously demonstrated that glutamate elevates
bAPP expression via a mechanism that requires the bio-
logical activity of ApoE [35]. Moreover, IL-1b has been
shown to influence the processing of bAPP [46]. There-
fore, we tested whether ApoE expression was responsive
to these agents and another derivative of bAPP: Ab1-42.
In both culture types, expression of ApoE mRNA was
elevated approximately two-fold by exposure to IL-1b,
Ab1-42, or glutamate for 20 h; the induction by sAPP
Figure 1 IL-1b induces ApoE expression in vivo. Proteins were extracted from the left cerebral cortex of unoperated rats (con), of rats
implanted in the right cerebrum with a pellet containing vehicle alone (sham), and of rats implanted in the right cerebrum with a slow-release
pellet containing 100 ng IL-1b (IL-1b pellet). A: RNA was extracted from the left cerebral cortex of con (n = 6), sham (n = 5), and IL-1b pellet (n
= 7) rats and subjected to gel-based RT-PCR for ApoE and GAPDH. B: Quantification of the ApoE mRNA (relative to that for GAPDH) by
densitometry of the RT-PCR image or by quantitative (real-time) RT-PCR (qRT-PCR); values reflect the percent of control as mean ± SEM. C:
Proteins were extracted from con (n = 3), sham (n = 3), and IL-1b pellet (n = 8) rats and subjected to western immunoblot analysis for ApoE. D:
Quantification of autoradiography; values reflect percent of control as mean ± SEM. *p≤0.05; **p < 0.01 versus control.
Figure 2 IL-1b induces increases in mRNAs encoding ApoE,
bAPP, and the proinflammatory factors IL-1b, ICE, IL-1a, and
TNF. RNA was extracted from the left cerebral cortex of unoperated
rats (Control), rats implanted in the right cerebrum with a pellet
containing vehicle alone (Sham), and rats implanted in the right
cerebrum with a slow-release pellet containing 100 ng IL-1b (IL-1b
Pellet); A: semi-quantitative RT-PCR was performed on the RNA. B:
Results quantified by densitometry showed significant differences in
mRNA levels from brains with IL-1b pellets compared to those with
sham pellets, or from those serving as controls; p≤0.05 for each
gene product.
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exceeded six-fold (Figure 4A). All of these agents were
found to elevate ApoE protein levels as well (Figure 4B).
The ability of glutamate and bAPP fragments to
impact ApoE was given additional relevance by demon-
stration of impacts of IL-1b on these agents. Levels of
glutamate released into neuronal culture medium was
elevated by IL-1b (Figure 5A). Likewise, IL-1b elevated
the levels of sAPP in the culture medium of primary
neurons in a dose-dependent fashion (Figure 5B). Gluta-
mate induction of ApoE in primary neurons was con-
firmed by immunofluorescence, which also documented
a larger induction by Ab1-42 (Figure 5C,D). Intriguingly,
coapplication of glutamate in combination with Ab1-42
reduced the induction to one on par with that of gluta-
mate alone (Figure 5D).
Regulation of ApoE expression by IL-1b, Ab, sAPP, and
glutamate is via multi-lineage kinase pathways
Each of the IL-1b-induced entities, sAPP and glutamate,
as well as Ab, were shown to elevate ApoE expression
in both primary neurons and NT2 cells (Figure 5). To
begin investigating the mechanisms involved in the
Figure 3 IL-1b induces expression of IL-1a, ApoE, and bAPP. Immunofluorescence was performed on tissue sections from the neocortex or
hippocampus (CA1) of unoperated rats (n = 4) (Control), from rats implanted with a pellet containing vehicle alone (n = 6) (Sham), and from
rats implanted with a slow-release pellet containing 100 ng IL-1b (n = 6) (IL-1b Pellet). Primary antibodies were A: ApoE, B: IL-1a, or C: bAPP;
the red immunofluorescence signal is countered by a blue DAPI stain of cell nuclei. Immunofluorescence was quantified as described in
Materials and Methods, and is expressed as mean ± SEM. All treatment conditions were significantly different from each other except with
regard to IL-1a, where only the comparison of IL-1b pellet to the other two treatments was significant (*p ≤0.05).
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induction of such ApoE expression, we focused on
multi-lineage kinases (MLKs) previously shown to regu-
late cytokine-induced AD-related proteins [47]. Primary
neurons and NT2 cells were incubated with inhibitors
of three principle MLK pathways, viz., the MEK/ERK
(U0126), MAPK-p38 (SB203580), and JNK (SP600125)
pathways. Constitutive expression of ApoE in both pri-
mary neurons and NT2 cells was unaffected by treat-
ment with these inhibitors (data not shown). However,
each of these MLK inhibitors suppressed induction of
ApoE by IL-1b (Figure 6A), Ab1-42 (Figure 6B), and sAPP
(Figure 6C) in both types of culture. Induction of ApoE
by glutamate in both NT2 and primary neurons was not
inhibited by SB203580, a MAPK-p38 inhibitor. Thus, reg-
ulation of ApoE expression by MLK pathways appears to
be somewhat selective and dependent on the effector of
its induction; in the case of glutamate, ERK and JNK
activity is involved but not MAPK-p38 (Figure 6D).
Discussion
The neuroinflammagenic potential of IL-1b is shown
here through its induction of synthesis of itself and
other proinflammatory cytokines including TNF, IL-1a,
IL-1b, as well as the latter’s maturation enzyme ICE.
The additional impact of IL-1b on neuronal ApoE pro-
duction shown here suggests that in neurological condi-
tions where the expression of proinflammatory
cytokines is elevated, the expression of IL-1-driven AD-
related proteins such as ApoE would be elevated as well.
Multiple MLKs–ERK, p38-MAPK, and JNK–were shown
to be involved in elevated expression of ApoE in neu-
rons exposed to IL-1b, Ab, or sAPP. The increased
expression of ApoE induced by glutamate was mediated
by ERK and JNK, but not by MAPK-p38. Together,
these findings have several implications for AD patho-
genesis, particularly with respect to conditions in which
neuroinflammation is prominent, especially those influ-
enced by APOE genotype.
The actions of IL-1 and the other agents tested here–
sAPP, Ab, and glutamate–create the possibility for com-
plex loops of influence analogous to the vicious circle of
neuroinflammatory events we have termed the Cytokine
Cycle [48]. Glutamate can elevate neuronal expression
of bAPP and its conversion to sAPP [42]. bAPP is ele-
vated in dystrophic neurites in and around plaques [49];
its breakdown into both sAPP and Ab can result in
induction of IL-1b in microglia [31,50]. In addition to
inducing IL-1b expression and release, sAPP and Ab
also stimulate microglia to release biologically relevant
levels of glutamate and its cooperative excitatory amino
acid D-serine [44,51,52]. Thus, future studies should
address the potential for each of these agents to act
indirectly through the elaboration of a key agent or
agents that can directly stimulate ApoE expression.
Key to interpretation of our findings–and, indeed, to
the role of APOE genotype in AD–is determining
whether elevation of ApoE levels would be beneficial or
harmful. Possession of the ε4 allele is associated with
enhanced deposition of Ab [53], consistent with in vitro
Figure 4 Elevation of ApoE expression in neuronal cells by
stimuli relevant to Alzheimer’s disease. Primary cortical neurons
or NT2 cells were treated with IL-1b (30 ng/ml), Ab1-42 (10 μM),
sAPP (30 nM), or Glu (50 μM) for 20 h. A: RNA was extracted from
the cultures for RT-PCR of ApoE and GAPDH as illustrated. The
results were quantified by densitometry, and values represent the
mean ± SEM for the ApoE amplimer relative to that for GAPDH. B:
Cell lysates from the cultures were equilibrated for total protein
levels and analyzed for ApoE content by western blot, also
quantified by densitometry (*p < 0.05, **p < 0.01).
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Figure 5 Potential for indirect effects of IL-1b. A: Primary cortical neurons were treated for 20 h with the indicated concentrations of IL-1b,
and glutamate levels were assessed in the medium (*p < 0.05). B: Primary cortical neurons were treated for 20 h with the indicated
concentrations of IL-1b, and sAPP levels were assessed in concentrated aliquots of the culture medium by western blot; *p < 0.05. C: Primary
cortical neurons were treated for 20 h with glutamate (50 μM) and Ab1-42 (10 μM) alone, or with a combination of the two; immunofluorescence
was performed for ApoE (green) and bAPP (red). D: The bar graph shows integrated fluorescence intensity quantified for the ApoE signal in the
cultures shown in panel C; n = 3 cultures for each treatment (*p < 0.05 compared to the untreated sample).
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Figure 6 Roles for p38-MAPK, ERK, and JNK in elevation of ApoE expression by IL-1b, Ab1-42, sAPP, and glutamate. Cultures of primary
cortical neurons or NT2 cells were treated for 20 h with A: IL-1b (30 ng/ml), B: Ab1-42 (10 μM), C: sAPP (30 nM), D: or glutamate (50 μM). In
parallel cultures, these agents were preceded by 5 μM of an inhibitor of p38-MAPK (SB), the ERK pathway (U0126), or JNK (JNKin). Lysates were
examined by western blot analysis of full-length ApoE, and autoradiographs were quantified by densitometry (bar graphs). Values represent
mean ± SEM (n = 4); *p < 0.05, **p < 0.01.
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studies wherein ApoE was shown to enhance Ab fibril-
logenesis [54]. In this regard, ApoE4 has been shown to
be more effective than ApoE3, fostering speculation that
replacement of the ε3 allele by ε4 merely enhances an
activity already present in ApoE3. This has been
described as a toxic gain of function, implying that over-
abundance of any ApoE–even ApoE2 or ApoE3–would
also create a gain in this function and thus be detrimen-
tal. Moreover, transient increases in cellular ApoE occur
in response to injuries that promote AD, e.g., traumatic
brain injury [55] and stroke [56]. ApoE4 is generally
reported to be present at higher steady-state levels than
ApoE3 in CSF or brain parenchyma [57-61], though
some studies have reported lower levels of total ApoE in
ε4-positive individuals [62,63].
In contrast to these connections to pathology, ApoE
provides neuroprotection in many paradigms, and ApoE
deficiency has proved detrimental in several respects
[64]. Therefore, inductions of ApoE by the stimuli we
tested may represent a compensatory response, meaning
that the distinction between ApoE3 and ApoE4 repre-
sents loss of a beneficial function. ApoE has anti-inflam-
matory effects, and even its interaction with Ab can
attenuate glial activation by the latter [65]. However,
ApoE3 is more effective than ApoE4 as an anti-inflam-
matory agent [31,65,66], so this putative compensatory
response may be inadequate in ε4-positive individuals
and thus allow more extensive propagation of the Cyto-
kine Cycle. Such an allele-specific compensatory
response may also extend to direct neuroprotective
activity. We previously reported that ApoE3 induces
bAPP expression but ApoE4 does not [35], confirming
the findings of Ezra et al. [67]. In this regard, elevations
of ApoE by the process of neuroinflammation, or other
stressors, would reflect a requisite role for the lipopro-
tein in enhancing the beneficial roles of bAPP and/or
other acute-phase response proteins. Thus, it would be
the inability of ApoE4 to participate in this chain of
salutary events that makes it detrimental. We have pre-
viously shown that the increase in ApoE brain levels
that occurs with aging continues to occur in AD, with a
large fraction being deposited in plaques [35]. This
increase in ApoE levels is distinguishable from changes
in bAPP, which rises with age but declines markedly in
AD [35]. This disease-associated severance of the coor-
dinate regulation of ApoE and bAPP further strengthens
the correlation of brain health with the coregulation of
these two proteins; to wit, with ApoE expression itself,
provided that the ApoE is not ApoE4.
Multi-lineage kinase pathways may be invoked in the
regulation of ApoE expression, and can themselves be
invoked by ApoE [68,69], suggesting a feedback loop
between MLK pathways and ApoE expression in neu-
rons. Our findings of involvement of multiple MLKs–
ERK, p38-MAPK, and JNK–in expression of ApoE in
neurons exposed to IL-1b, Ab, or sAPP, together with
previous reports of ERK pathway invocation of ApoE
expression and vice versa, are consistent with the exis-
tence of a complex feedback system that may be impor-
tant in acute-phase responses to neuronal injury as well
as potential exacerbation of neurodegenerative events.
Our finding that glutamate regulates ApoE expression
via ERK and JNK, but not by p38-MAPK pathways may
be indicative of a correlation between glutamatergic
induction of ApoE and neuronal survival. Excitotoxic
effects of glutamate are largely dependent upon activa-
tion of extrasynaptic NMDA receptors, p38-MAPK, and
the inhibition of ERK signaling; synaptic receptors, on
the other hand, appear to activate ERK and promote
survival [70-72].
In conclusion, the induction of neuronal ApoE by
either neuroinflammatory or excitotoxic agents or neu-
rotoxins, acting through MLK pathways suggests that
alterations in these signaling pathways, together with
other neuropathological entities in AD brain, may have
consequences for ApoE expression. Differences in this
expression may be critical, considering the role of APOE
genotype in AD risk. The response of ApoE to IL-1b we
show here in rodent brain suggests that elevation of IL-
1 leads to the increases in ApoE that we and others
have observed in the AD brain. This may have added
significance with regard to the self-propagating nature
of IL-1-driven cascades, especially when such cascades
are instigated in the context of an ε4 allele of APOE.
While induction of ApoE2 or ApoE3 may be anti-
inflammatory or neuroprotective, and thereby act as a
self-limiting influence on IL-1-driven cascades, ApoE4
may fail to participate and leave the brain vulnerable to
prolonged activation of a maladaptive cycle.
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